Bristol Myers Squibb Company (BMY) vs Sanofi (SNY)
Bristol Myers Squibb Company and Sanofi are both Drug Manufacturers General companies. Bristol Myers Squibb Company is the larger, with a market value of $125.9B against $97.4B — 1.3× the size. Bristol Myers Squibb Company trades at the lower P/E: 13.8× against 21.5×. Sanofi grew revenue faster over the last twelve months: 21.3% against 3.11%. Bristol Myers Squibb Company has the higher net margin (18.9% vs 8.22%) and the higher return on invested capital (13.7% vs 6.58%). Both pay a dividend; Bristol Myers Squibb Company yields more (5.04% vs 4.40%). Across the 23 metrics below, Bristol Myers Squibb Company leads on 12 and Sanofi on 11.
Valuation
Profitability
| Metric | BMY | SNY | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 70.16% | 72.78% | 72.77% |
| Operating margin | 24.22% | 18.24% | 18.90% |
| Net margin | 18.87% | 8.22% | 8.27% |
| Free cash flow margin | 23.26% | 25.53% | 17.25% |
| Return on equity | 46.63% | 5.87% | 6.97% |
| Return on assets | 10.18% | 3.21% | 2.76% |
| Return on invested capital | 13.69% | 6.58% | 6.30% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack